ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1957

Prevalence and Associated Factors of Vitamin D Insufficiency and Deficiency in 4,793 Japanese Patients with Rheumatoid Arthritis

Takefumi Furuya1, Takayuki Hosoi2, Eiichi Tanaka3, Ayako Nakajima4, Atsuo Taniguchi5, Shigeki Momohara1 and Hisashi Yamanaka1, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Department of Clinical Research and Development, National Center for Geriatrics and Gerontology, Aichi, Japan, 3Tokyo Women's Medical University, Tokyo, Japan, 4Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 5Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: 25 OH D Vitamin insufficiency, Health Assessment Questionnaire, Japanese, Osteoporosis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoporosis and Metabolic Bone Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Vitamin D (25[OH]D) insufficiency and deficiency is reported to be common in patients with rheumatoid arthritis (RA) and is associated with increased disease activity of RA, although there are limited reports of Japanese RA patients in the literature. Among osteoporosis patients treated with bisphosphonates, vitamin D status and concomitant use of active vitamin D3 analogs are both reported to affect the increase in bone mineral density (BMD). Our purpose was to define the prevalence and associations of 25(OH)D insufficiency and deficiency with clinical characteristics in Japanese patients with RA.

Methods: Serum 25(OH)D levels, laboratory data, and clinical data were obtained from 4,793 patients with RA (4,075 women, 718 men, mean age 59.7 years) who participated in the Institute of Rheumatology Rheumatoid Arthritis (IORRA) observational cohort study in April and May of 2011. Their serum vitamin D levels were evaluated using radioimmunoassays. Insufficiency was defined as a concentration < 20 ng/mL and deficiency as < 10 ng/mL. Associations of 25(OH)D insufficiency and deficiency with patient characteristics were examined using multivariate logistic regression.

Results: The mean (SD) serum 25(OH)D level was 16.9 (6.1) ng/mL. The prevalence of 25(OH)D insufficiency and deficiency among all the patients in the study were 71.8% and 11.5%, respectively. Serum 25(OH)D levels were significantly different (P < 0.05) between the patients with (n = 507, 10.6%) and without active vitamin D3 analogs. Among the patients treated with bisphosphonates (n = 1,130), insufficiency and deficiency were 71.5% and 10.4%, respectively. In multivariate analyses, female gender (odds ratios [OR] 2.38, 95 confidence interval [CI] 1.88-2.92 and OR 2.01, 95% CI 1.41-2.91), age (per 10 years, OR 0.72, 95% CI 0.68-0.77 and OR 0.67, 95% CI 0.62-0.73), Japanese health assessment questionnaire (J-HAQ) disability scores (OR 1.20, 95% CI 1.07-1.36 and OR 1.63, 95% CI 1.40-1.92), serum total cholesterol levels (per 10 mg/100mL, OR 0.96, 95% CI 0.94-0.98 and OR 0.95, 95% CI 0.92-0.98), serum alkaline phosphate level (per 10 IU/L, OR 1.01, 95% CI 1.00-1.02 and OR 1.02, 95% CI 1.00-1.03), and use of non-steroidal anti-inflammatory drugs (NSAIDs) (OR 1.27, 95% CI 1.11-1.46 and OR 1.25, 95% CI 1.02-1.54) were associated (P < 0.05) with vitamin D insufficiency and deficiency, respectively. Body mass index (BMI) and use of active vitamin D3 analogs (OR 0.96, 95% CI 0.93-0.99 and OR 0.69, 95% CI 0.48-0.97, respectively) were significantly associated with vitamin D deficiency alone. The Disease Activity Score including 28 joints (DAS28) was not significantly associated with either vitamin D insufficiency or deficiency in this patient population.

Conclusion: Vitamin D insufficiency and deficiency are common in Japanese patients with RA, as previously reported for patients of other ethnicities. Female gender, younger age, high HAQ disability score, serum levels of total cholesterol and alkaline phosphate and NSAID use appear to be associated with both vitamin D insufficiency and deficiency in Japanese patients with RA. Low BMI and disuse of active vitamin D3 analogs, however, appear to correlate only with vitamin D deficiency in Japanese patients with RA.


Disclosure:

T. Furuya,
None;

T. Hosoi,
None;

E. Tanaka,
None;

A. Nakajima,
None;

A. Taniguchi,
None;

S. Momohara,
None;

H. Yamanaka,

Abbott Japan Co. Ltd., AstraZeneca K.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Janssen Pharmaceutical K.K. Japan, Mitsubishi Tanabe Pharma Corporation, Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Limite,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-associated-factors-of-vitamin-d-insufficiency-and-deficiency-in-4793-japanese-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology